While NGM Biopharmaceuticals' EPS beat may provide some positive sentiment, the significant miss on sales forecasts and the drastic decrease in sales compared to the previous year could raise concerns about the company's revenue generation capabilities and overall financial health. This mixed result makes the short-term impact on the stock price uncertain, hence a neutral score.